Docetaxel 20mg
| Product Overview | |
| Generic Name | Docetaxel 20mg |
| Brand Name(s) | Taxotere |
| Form | IV concentrate/injection vials |
| Strength | 20 mg |
| Therapeutic Class | Antineoplastic taxane (mitotic inhibitor) |
| ATC Code | L01CD02 |
| Manufacturing & Regulatory | |
| Manufacturer | Generic |
| Country | Canada, USA, India |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II/III |
| COFEPRIS | 010.000.5457.02 |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 units |
| Shelf Life | 36 months |
| Storage | 2–8 °C |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| CTD Summary | Full CTD dossier proprietary; available under commercial agreement/license |
Description
Docetaxel is an injectable antineoplastic chemotherapy agent used in oncology for the treatment of multiple solid tumors, including breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancers. It is generally administered by intravenous infusion under specialist oncology supervision and may be used alone or in combination with other chemotherapy or supportive medicines depending on the approved treatment protocol
